Insider Buying: Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Acquires 100,000 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) major shareholder Paul B. Manning bought 100,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were acquired at an average price of $1.63 per share, for a total transaction of $163,000.00. Following the completion of the purchase, the insider now owns 16,566,667 shares in the company, valued at $27,003,667.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Taysha Gene Therapies Trading Up 1.2 %

Shares of NASDAQ:TSHA opened at $1.72 on Monday. Taysha Gene Therapies, Inc. has a 12-month low of $0.50 and a 12-month high of $3.89. The business has a 50 day moving average of $2.49 and a two-hundred day moving average of $1.62. The company has a market capitalization of $321.57 million, a PE ratio of -0.66 and a beta of 0.13.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently made changes to their positions in the company. Swiss National Bank increased its holdings in Taysha Gene Therapies by 9.3% in the first quarter. Swiss National Bank now owns 41,000 shares of the company’s stock valued at $267,000 after buying an additional 3,500 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Taysha Gene Therapies by 85.1% in the 1st quarter. JPMorgan Chase & Co. now owns 439,804 shares of the company’s stock valued at $2,868,000 after purchasing an additional 202,245 shares in the last quarter. Vanguard Group Inc. raised its holdings in Taysha Gene Therapies by 14.5% in the 1st quarter. Vanguard Group Inc. now owns 1,012,164 shares of the company’s stock worth $6,599,000 after purchasing an additional 128,517 shares during the period. Renaissance Technologies LLC purchased a new position in Taysha Gene Therapies during the first quarter worth approximately $1,633,000. Finally, UBS Group AG boosted its position in Taysha Gene Therapies by 33.2% during the first quarter. UBS Group AG now owns 67,980 shares of the company’s stock worth $443,000 after purchasing an additional 16,944 shares in the last quarter. 25.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on TSHA shares. Canaccord Genuity Group dropped their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, September 20th. JMP Securities reiterated a “market outperform” rating and set a $4.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, August 15th. Truist Financial reduced their price objective on Taysha Gene Therapies from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, September 20th. Chardan Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, August 15th. Finally, Cantor Fitzgerald increased their price target on shares of Taysha Gene Therapies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Wednesday, November 15th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.89.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.